Compare Incyte Corporation (INCY) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lithium Americas Corp — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Lithium Americas Corp trades at $3.28 (market cap $1.18B). The key difference: Incyte Corporation is far larger — about 20.8× Lithium Americas Corp's market cap, and Incyte Corporation is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| INCY | LAC | |
|---|---|---|
Market Cap | $24.54B | $1.18B |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $10.05 |
52-Week Low | $81.61 | $2.71 |
Enterprise Value | $20.04B | $1.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Lithium Americas (LAC) trades at $3.25 with mixed technical signals showing a bullish overall trend but neutral oscillators. The company reported negative profitability metrics with ROE at -11.35% and net income of -$122.09M for 2025, though it secured $175M financing for Thacker Pass construction. Recent earnings show volatility with two beats and one miss in the last four quarters.
LAC faces significant execution risks with substantial capital expenditures needed, but analyst sentiment remains positive with 7 buy ratings and no sell recommendations. The stock's valuation at 0.88 P/B suggests potential upside if lithium demand recovers, though negative cash flow from operations and high investing outflows present near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
